The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV FiTNEss trial
In this interview, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, shares findings from the UK-MRA FiTNEss trial (NCT03720041), a study that aimed to investigate the use of frailty-adapted therapy in older transplant-ineligible patients with multiple myeloma. While the primary endpoint of early treatment cessation within 60 days did not show a significant difference between the two arms, the study found evidence of improved event-free survival (EFS) and overall survival (OS) in patients receiving frailty-adjusted therapy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
